Canopus BioPharma currently has two drug candidates in Phase II clinical studies both in the USA and South Africa. These studies are evaluating Canopus’ Antiviral (CB5300 for Hepatitis C) and Cancer Supportive Care (Oltipraz for Mucositis) drug candidates. As well as this, Canopus has a large pipeline of additional technologies in development. These include stem cell proliferation agents, novel antibacterial agents and the Influenza antiviral Zofroxia™.
Canopus has developed major new technologies and collaborated with some of the most prestigious research institutes in the world in an effort to commercialise its leading drug candidates. Canopus works closely with Fox Chase Cancer Center USA, Harvard University (Biomodels) Boston, Wisconsin Alumni Research Foundation Madison, Swinburne University Australia and the Sun Yat-sen University in China.